These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37952003)
21. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
23. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. Allen JD; Ray S; Ross TM PLoS One; 2018; 13(9):e0204284. PubMed ID: 30265682 [TBL] [Abstract][Full Text] [Related]
24. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638 [TBL] [Abstract][Full Text] [Related]
25. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710 [TBL] [Abstract][Full Text] [Related]
26. Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system. Friel D; Co M; Ollinger T; Salaun B; Schuind A; Li P; Walravens K; Ennis FA; Vaughn DW Influenza Other Respir Viruses; 2021 Jan; 15(1):110-120. PubMed ID: 32889792 [TBL] [Abstract][Full Text] [Related]
27. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P Vaccine; 2022 Mar; 40(10):1472-1482. PubMed ID: 35125224 [TBL] [Abstract][Full Text] [Related]
29. Comparison of adjuvants to optimize influenza neutralizing antibody responses. Rudicell RS; Garinot M; Kanekiyo M; Kamp HD; Swanson K; Chou TH; Dai S; Bedel O; Simard D; Gillespie RA; Yang K; Reardon M; Avila LZ; Besev M; Dhal PK; Dharanipragada R; Zheng L; Duan X; Dinapoli J; Vogel TU; Kleanthous H; Mascola JR; Graham BS; Haensler J; Wei CJ; Nabel GJ Vaccine; 2019 Sep; 37(42):6208-6220. PubMed ID: 31493950 [TBL] [Abstract][Full Text] [Related]
30. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411 [TBL] [Abstract][Full Text] [Related]
31. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441 [TBL] [Abstract][Full Text] [Related]
33. The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines. Nagashima K; Dzimianski JV; Han J; Abbadi N; Gingerich AD; Royer F; O'Rourke S; Sautto GA; Ross TM; Ward AB; DuBois RM; Mousa JJ J Immunol; 2022 Jul; 209(1):5-15. PubMed ID: 35697384 [TBL] [Abstract][Full Text] [Related]
34. A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge. Sia ZR; He X; Zhang A; Ang JC; Shao S; Seffouh A; Huang WC; D'Agostino MR; Teimouri Dereshgi A; Suryaprakash S; Ortega J; Andersen H; Miller MS; Davidson BA; Lovell JF Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050027 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311 [TBL] [Abstract][Full Text] [Related]
36. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361 [TBL] [Abstract][Full Text] [Related]
37. Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin. Wang W; Alvarado-Facundo E; Vassell R; Collins L; Colombo RE; Ganesan A; Geaney C; Hrncir D; Lalani T; Markelz AE; Maves RC; McClenathan B; Mende K; Richard SA; Schofield C; Seshadri S; Spooner C; Utz GC; Warkentien TE; Levine M; Coles CL; Burgess TH; Eichelberger M; Weiss CD Clin Infect Dis; 2021 Dec; 73(11):e4312-e4320. PubMed ID: 32898271 [TBL] [Abstract][Full Text] [Related]
38. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753 [TBL] [Abstract][Full Text] [Related]